In recent years, there has been a lot of concern about an increased risk of suicidal ideation and behavior in persons prescribed antidepressant medications. This led to a boxed warning by the FDA.
Not surprisingly, therefore, this article, published in BMJ recently, received a huge amount of attention in the press.
Both the FDA warning and the concern of patients and their families make it essential that those who prescribe antidepressants stay up-to-date on data about these risks. We must be prepared to discuss this and similar studies with patients and their families.